BeStock  
Stocks › Biotechnology › IONS

Ionis Pharmaceuticals IONS

US equityMarket cap rank #2142Biotechnology
$26.58 −$0.64 (-2.35%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $26.76 +0.68%
Open$26.93
Prev close$27.22
Day range$26.53 – $28.07
Volume3.19M
Market cap$4.43B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$242.72M+54.9% YoY
Operating profit-$130.68M+18.4% YoY
Net profit-$109.97M+14.5% YoY
Diluted EPS-$0.66+17.5% YoY
Free cash flow-$193.63M-39.9% YoY
Operating cash flow-$179.42M

Revenue, last 8 quarters

$226.6MDec '24$131.6MMar '25$452.0MJun '25$156.7MSep '25$203.3MDec '25$246.1MMar '26$267.9MJun '26$242.7MSep '26

Net profit, last 8 quarters

$-104.3MDec '24$-146.9MMar '25$123.6MJun '25$-128.6MSep '25$-229.4MDec '25$-92.5MMar '26$-114.6MJun '26$-110.0MSep '26

Diluted EPS by quarter

-0.66Dec '24-0.93Mar '250.70Jun '25-0.80Sep '25-1.41Dec '25-0.56Mar '26-0.69Jun '26-0.66Sep '26

Free cash flow by quarter

$-144.2MDec '24$-164.0MMar '25$137.1MJun '25$-138.4MSep '25$-160.4MDec '25$-816.1MMar '26$547.3MJun '26$-193.6MSep '26

Annual revenue

$729.3MFY20$810.5MFY21$587.4MFY22$787.6MFY23$705.1MFY24$943.7MFY25

Profitability & balance sheet

Gross margin98.2%
Operating margin-58.8%
Net margin-56.9%
Return on equity-108.1%
Return on assets-18.4%
Return on invested capital-24.5%
Current ratio5.43
Liabilities / assets86.5%
Cash & investments$1.88B
Total debt$1.63B
Net cash (debt)$254.72M

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Revenue as Reported $242.72M $267.95M $246.09M $943.71M $203.33M
Total Operating Revenue $242.72M $267.95M $246.09M $943.71M $203.33M
Cost of Revenue $3.32M $2.74M $3.00M $15.91M $7.96M
Gross Profit $239.40M $265.21M $243.09M $927.80M $195.37M
Operating Expense $370.08M $367.51M $360.57M $1.31B $409.85M
Selling and Admin Expenses $154.20M $150.40M $150.40M $393.90M $130.20M
-General & Admin Expense $154.20M $150.40M $150.40M $393.90M $130.20M
Research & Development $215.88M $217.11M $210.17M $915.62M $279.65M
Operating Profit -$130.68M -$102.30M -$117.48M -$381.72M -$214.47M
Net Non-Operating Interest Income (Expense) -$8.73M -$22.11M -$22.54M -$90.58M -$22.76M
Non-Operating Interest Expense $7.03M $20.51M $20.34M $84.28M $21.06M
Total Other Finance Costs $1.70M $1.60M $2.20M $6.30M $1.70M
Other Income (Expense) $29.35M $11.04M $47.61M $92.63M $9.23M
Gain on Sale of Security $29.07M $10.05M $48.07M $107.99M $25.52M
Other Non-Operating Income (Expenses) $277,000.00 $987,000.00 -$456,000.00 -$15.36M -$16.29M
Pretax Profit -$110.11M -$113.38M -$92.31M -$379.60M -$227.92M
Tax -$141,000.00 $1.26M $218,000.00 $1.79M $1.48M
Net Profit -$109.97M -$114.65M -$92.53M -$381.39M -$229.39M
Profit from Continuing Operations -$109.97M -$114.65M -$92.53M -$381.39M -$229.39M
Net Income to Parent Company -$109.97M -$114.65M -$92.53M -$381.39M -$229.39M
Net Income to Common Stockholders -$109.97M -$114.65M -$92.53M -$381.39M -$229.39M
Basic EPS -$0.66 -$0.69 -$0.56 -$2.38 -$1.41
Diluted EPS -$0.66 -$0.69 -$0.56 -$2.38 -$1.41

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $2.91B $2.99B $3.45B $3.52B $3.52B
Total Current Assets $2.36B $2.49B $2.94B $2.99B $2.99B
Cash and Cash Equivalents & Short-Term Investments $1.88B $2.05B $1.92B $2.68B $2.68B
-Cash and Cash Equivalents $296.30M $350.07M $173.38M $372.26M $372.26M
-Short Term Investments $1.59B $1.70B $1.75B $2.31B $2.31B
Receivables $88.34M $58.85M $73.68M $66.06M $66.06M
-Other Receivables $88.34M $58.85M $73.68M $66.06M $66.06M
Inventory $28.58M $50.83M $5.56M $10.05M $10.05M
Other Current Assets $360.68M $327.01M $306.08M $237.09M $237.09M
Total Non-Current Assets $551.09M $503.23M $513.02M $533.20M $533.20M
Net PPE $390.09M $386.69M $377.47M $361.60M $361.60M
-Gross PPE $390.09M $386.69M $377.47M $470.68M $470.68M
Other Non-Current Assets $161.00M $116.54M $135.56M $171.60M $171.60M
Total Liabilities $2.52B $2.55B $2.96B $3.03B $3.03B
Total Current Liabilities $435.29M $315.64M $716.59M $781.57M $781.57M
Payables $27.22M $50.58M $28.90M $30.80M $30.80M
-Accounts Payable $27.11M $47.70M $26.03M $28.08M $28.08M
-Total Tax Payable $109,000.00 $2.88M $2.87M $2.71M $2.71M
Current Accrued Expenses $116.18M $115.78M $126.55M $106.09M $106.09M
Short-Term Debt and Capital Lease Obligation $22.12M – $432.50M $454.69M $454.69M
-Current Debt $22.12M – $432.50M $454.69M $454.69M
Current Deferred Liabilities $70.20M $73.84M $69.20M $73.76M $73.76M
Other Current Liabilities $138.19M $25.15M $23.39M – –
Total Non-Current Liabilities $2.08B $2.24B $2.24B $2.25B $2.25B
Long Term Debt and Capital Lease Obligation $1.61B $1.61B $1.61B $1.61B $1.61B
-Long Term Debt $1.34B $1.35B $1.35B $1.35B $1.35B
-Long Term Capital Lease Obligation $262.48M $262.48M $259.22M $262.38M $262.38M
Non-Current Deferred Liabilities $48.76M $63.03M $75.75M $92.00M $92.00M
Other Non-Current Liabilities $427.84M $562.57M $557.77M $551.35M $551.35M
Total Equity $393.64M $439.74M $491.41M $489.09M $489.09M
Stockholders' Equity $393.64M $439.74M $491.41M $489.09M $489.09M
Capital Stock $166,000.00 $166,000.00 $166,000.00 $163,000.00 $163,000.00
-Common Stock $166,000.00 $166,000.00 $166,000.00 $163,000.00 $163,000.00
Additional Paid-In Capital $3.38B $3.31B $3.25B $3.15B $3.15B
Retained Earnings -$2.95B -$2.84B -$2.72B -$2.63B -$2.63B
Gains/Losses Not Affecting Retained Earnings -$39.82M -$33.90M -$31.02M -$25.28M -$25.28M
Restricted Cash – – $632.51M – –
-Accumulated Depreciation – – – -$109.08M -$109.08M

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$179.42M $565.53M -$792.82M -$268.58M -$137.71M
Net cash flow from continuing operations -$179.42M $565.53M -$792.82M -$268.58M -$137.71M
Net Income from Continuing Operations -$109.97M -$114.65M -$92.53M -$381.39M -$229.39M
Gain/Loss from Continuing Operations -$8.71M $10.62M -$22.54M $4.06M $17.14M
Depreciation & Depletion & Amortization $7.86M $7.64M $7.45M $22.69M $7.34M
Other Non-Cash Items -$7.82M $8.46M $7.84M $27.13M $5.70M
Change in Working Capital -$101.14M $611.21M -$730.12M -$51.22M $23.86M
-Change in Receivables -$29.50M $14.84M -$7.63M $26.13M -$41.45M
-Change in Inventory -$22.00M -$24.96M $338,000.00 -$13.67M $926,000.00
-Change in Payables and Accrued Expense -$9.66M $27.93M -$62.28M $36.59M -$9.45M
-Change in Other Current Assets -$22.08M -$30.88M -$7.39M -$33.21M $90.28M
-Change In Other Working Capital -$17.91M $624.27M -$653.17M -$67.05M -$16.45M
Net cash flow from investing $99.88M $23.50M $536.82M -$277.78M -$419.51M
Net Cash Flow from Continuing Investing Activities $99.88M $23.50M $536.82M -$277.78M -$419.51M
Net PPE Purchase and Sale -$12.71M -$16.08M -$21.76M -$51.44M -$21.29M
Net Intangibles Purchase and Sale -$1.50M -$2.15M -$1.49M -$5.64M -$1.37M
Net Investment Purchase and Sale $114.09M $41.73M $560.07M -$220.69M -$396.85M
Financing Cash Flow $25.79M -$412.29M $57.26M $675.84M $591.18M
Net Cash Flow from Continuing Financing Activities $25.79M -$412.29M $57.26M $675.84M $591.18M
Net Issuance Payments Of Debt -$43,000.00 -$432.55M -$44,000.00 $502.19M $502.31M
Net Common Stock Issuance $25.83M $20.26M $57.30M $192.60M $107.82M
Ending Cash Balance $296.30M $350.07M $173.38M $372.26M $372.26M
Net Change in Cash -$53.75M $176.73M -$198.74M $129.48M $33.96M
Beginning Cash Balance $350.07M $173.38M $372.26M $242.08M $338.34M
Effect of Exchange Rate Changes -$11,000.00 -$50,000.00 -$138,000.00 $702,000.00 -$43,000.00
Free Cash Flow -$193.63M $547.30M -$816.07M -$325.67M -$160.37M
Net Other Financing Charges – – – -$18.95M –

Discussion

No comments yet — be the first to weigh in on IONS.

Sign in to join the discussion.

Scroll to Top